YARDLEY, Pa., November 4, 2020 / PRNewswire / – SOFIE Biosciences, Inc. (“SOFIE”), an established radiopharmaceutical supplier and worldwide radiopharmaceutical contract manufacturing organization, and Jubilant Radiopharma, a business division of Jubilant Pharma Ltd, announced that the two organizations have entered into a strategic partnership. Under the terms of the partnership, Jubilant Pharma, one of its wholly owned subsidiaries, will be a strategic partner for SOFIE with a 25% equity holding, allowing SOFIE to grow production capacity, further expand its therapeutic pipeline, and support the novel PET will help clinical manufacturing and distribution within the US
“SOFIE is a hub of innovation, and with Jubilant’s deep experience, uncompromising quality and customer-centric operations, we will bring game-changing therapeutic solutions to nuclear medicine,” said Sergio Calvo, President of Jubilant’s radiopharmaceuticals division.
“With this new relationship, SOFIE achieves another achievement in our innovation strategy,” Philipp Czernin, Chief revenue officer of SOFIE commented. “By engaging a well-established industry partner such as Jubilant Radiopharma, SOFIE will leverage the combined market presence and micro-organizational structure to deliver compounds of success to the nuclear medicine community. With related distribution capabilities and a highly complementary product portfolio of SPECT and PET radiopharmaceuticals, both companies are well placed to create single-vendor opportunities in select geographies. “
As part of the agreement, Jubilant Radiopharma will invest US $ 25m In SOFIE Biosciences. This funding will help speed up the readiness deadline for SOFIE’s state-of-the-art Theranostics Center of Excellence Manufacturing Center. Totowa, New Jersey, As well as furthering the development of their fibroblast activation protein inhibitor (FAPI) program. Patrick phelps, President and chief executive officer of SOFIE, stated, “Under this strategic partnership, SOFIE is excited to meet the growing need to manufacture highly specialized radiopharmaceuticals, as well as becoming the first therapeutic production center for FAPI in the US. FAPI has been praised worldwide for its value as a leading Miracle-generation therapeutic agent with the potential to enhance the detection and treatment of a variety of oncology diseases, and with the investment and support of Jubilant Radiopharma Believe, we can accelerate the development and commercialization of this exciting family of compounds. “
“This agreement is yet another demonstration of Jubilant Radiopharma’s long-term commitment to the global nuclear medicine community. Our teams are dedicated to bringing the Miracle generation of successful products and industry-leading services to healthcare providers worldwide as part of our mission to improve life through nuclear medicine. Pramod Yadav, CEO Jubilant Pharma Limited.
About SOFIE Biosciences, Inc.
The vision of SOFIE is to improve patient outcomes by developing and delivering molecular diagnostics and therapies. With its strong radiopharmaceutical production and distribution network, mature contract manufacturing services and now, high-value theranostic intellectual property, SOFIE is ready to deliver on the promise of nuclear medicine.
For more information about SOFIE Biosciences, Inc.
E-mail: [email protected]
visit our website @ https://sofie.com
About Jubilant Pharma Ltd.
Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore And a wholly owned subsidiary of Jubilant Life Sciences Ltd., an integrated global pharmaceutical company engaged in the manufacture and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and sterile injectables and contract manufacturing through six US FDA . Manufacturing facilities in the US Canada And India And a network of 49 radiopharmacies in the US, the company has a team of approximately 5,200 multicultural people worldwide and is committed to delivering value to its customers spanning more than 75 countries. It is well recognized as a ‘partner of choice’ by leading pharmaceutical companies globally.
About Jubilant Radiopharma
Jubilant Radiopharma of Jubilant Pharma Ltd, Jubilant Radiopharma, is an industry-leading radiopharmaceutical business globally developing, manufacturing, commercializing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of “Improving Lives Through Nuclear Medicine” And focuses on distribution. Scale. Company is market leader North America Other products such as I-131 products (for thyroid disorder and cancer diagnosis and treatment), MAA (lung perfusion imaging), DTPA (kidney, brain imaging) and MDP (bone imaging), and Sestamibi (myocardial perfusion imaging). Also does marketing. , Glauceptate (brain and kidney imaging), and rubidium-82 generator (PET cardiology).
For more information about Jubilant Radiopharma
E-mail: [email protected] (Robert sgroi, Director of marketing)
visit our website @ www.jubilantradiopharma.com
For more information about Jubilant Pharma Ltd.
E-mail: [email protected] (Hemant Bakhru, Head – Investor Relations)
visit our website @ www.jubilantpharma.com
Improvement in life through nuclear medicine
Content is by PR Newswire. Tech Media is not responsible for the content provided or any link related to this content. Tech Media is not responsible for the accuracy, timeliness or quality of content.